Navigation Links
The current state of lung cancer treatment
Date:12/11/2012

l chemotherapies, and with much reduced side effects.

But with this great promise of picking off cancer varieties one-by-one according to their oncogenes comes the challenge of testing drugs that are effective in perhaps only one of every 100 lung cancer patients. The challenge is twofold: enrolling enough patients on a clinical trial to make the results meaningful, and securing funding for a trial in which the drug will only be marketable to a small slice of the lung cancer population.

"How do you get drug approvals for what we'd normally call orphan diseases?" Bunn asks.

Then, Bunn points to the major challenge of staying ahead of lung cancer as it mutates in response to these targeted first-line drugs. "Targeted therapies don't cure patients yet," Bunn says. Instead, lung cancer eventually mutates around the drug's effectiveness. "And so we have to discover the most rational combinations and see if these combinations allow complete response," Bunn says.

In addition to therapies targeting oncogenes, Bunn describes completely new approaches to treating the disease, including Phase III clinical trials of lung cancer vaccines that aid the body's immune response against the cancer, and the search for ways to promote the function of tumor-suppressor genes that are commonly turned off in cancers.

What is clear is that after many years of chemotherapy and radiation, we're in the midst of an explosion in novel lung cancer treatment options.

"In the coming few years it is likely that we will identify additional 'actionable' molecular drivers treated with specific oral inhibitors," Bunn says. "We're already up to 30 or 40 percent of lung cancers that are susceptible to targeted therapies. I don't know if we'll reach 100 percent but the number is certain to grow."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
2. Triple negative breast cancer symposium highlights current advances
3. Why current strategies for fighting obesity are not working
4. Current and former smokers at risk for recurrent hepatitis post-liver transplantation
5. DMP module on heart failure: Current guidelines indicate some need for revision
6. Study suggests new way to prevent recurrent ear infections
7. Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
8. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
9. Benefit of PET or PET/CT in recurrent bowel cancer is not proven
10. Study reveals how cancer drug causes diabetic-like state
11. New drug prevents spread of human prostate cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 06, 2015 Dr. Amy Reed, who ... a ban on the use of power morcellators ( http://www.morcellatorlawsuit2015.com ... the cancer that prompted the launch of their public health ... week that the 41-year-old mother of six had recently undergone ... in her spine. Dr. Reed had been in remission for ...
(Date:3/6/2015)... March 06, 2015 Sanjay Gupta, ... deliver a keynote address at ATA 2015, the ... and Trade Show and world’s largest telemedicine, telehealth ... neurosurgeon, delivers medical correspondence for several of CNN’s ... and documentaries including his DuPont Award winning WEED ...
(Date:3/6/2015)... Ticket Down is a reliable source for authentic ... Clara, California. This state-of-the-art stadium opened on July 17, ... events. , The “Kick the Dust Up Tour” featuring country ... the west coast and Levi’s Stadium. The show at the ... August 29 and fans of the award-winning artist will be ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 ... the leader in the natural products coffee drinks category, ... 100 Cleanest Packaged Foods Awards for its Double ... puts packaged foods to the test to find the ... they must “taste absolutely delicious.” , “As a company ...
(Date:3/6/2015)... San Jose, California (PRWEB) March 06, 2015 ... cancer is one of the most common forms of ... women worldwide. Breast cancer can be screened through various ... among others. Mammography however remains the gold standard technique ... factors such as cost, time taken for the procedure, ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 2Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 3Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 4Health News:CNN’s Dr. Sanjay Gupta Among Headliners at American Telemedicine Association 2015 Annual Meeting 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Prevention Magazine Names Califia Farms Winner of 2015 Cleanest Packaged Food Award 2Health News:Prevention Magazine Names Califia Farms Winner of 2015 Cleanest Packaged Food Award 3Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3
... removed from product -, WAYNE, N.J., May 19 ... of the liquid Leukine(R),(sargramostim) 500 mcg vial has been ... and is now available for patients and physicians,in the ... disodium),which was in the product,s liquid 500 mcg vial ...
... census, Americans office workers spend an average of 52 ... Many recent studies on job satisfaction have shown that ... under artificial light in windowless offices, report reduced job ... make office environments more conducive to productivity and employee ...
... initiation and progression of prostate cancer have eluded ... researchers have identified a specific gene expression profile ... for future treatments. The findings, published in BioMed ... genes that are differentially expressed in certain prostate ...
... VIEW, Calif., May 19 Alexza,Pharmaceuticals, Inc. ... Jeffrey S.,Williams has rejoined the company in ... Ltd., a wholly owned subsidiary of Alexza. ... the Alexza,subsidiary in Singapore and establishing potential ...
... LLC, the world,s,first mobile voice-activation solution for e-Health ... J. Zecchini as its Chief,Operating Officer and Chief ... be responsible for all operations and technology functions., ... to our MediVoice team," said,Anthony V. Milone, Board ...
... CLARA, Calif., May 19 FLARE Santa,Clara HIV ... (AACI), The Billy DeFrank Center Lesbian and Gay ... Health Department, Asian,& Pacific Islander Wellness Center present ... Thursday, May 22, 2008 from 11 to 2 ...
Cached Medicine News:Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 2Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 3Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 4Health News:Greener offices make happier employees 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3Health News:MediVoice Announces Appointment of Edward J. Zecchini as Chief Operating Officer & Chief Technology Officer 2
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... N.J. , March 5, 2015 CANTEL MEDICAL ... for its second quarter ended January 31, 2015 on Thursday, ... call to discuss the results at 11:00 AM ET. ... 407-8033 approximately 5 to 10 minutes before the beginning of ... replay of the call will be available from Thursday, March ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... WALTHAM, Mass., Jan. 4, 2011 Syndax Pharmaceuticals, Inc., ... Horobin, M.D., the company,s president and CEO, will present ... 2011 at 10:00 a.m. PT at the Parc 55 ... include the recently reported results from a randomized phase ...
... Jan. 4, 2011 STAAR Surgical Company (Nasdaq: ... and marketer of minimally invasive ophthalmic products, today ... ICL implants in patients has exceeded 200,000.  Since ... used in refractive eye surgery as an alternative ...
Cached Medicine Technology:STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 2STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 3
... SDS Recall marketing software enables the efficient ... The module also has many built-in time ... auto capitalization of name fields and numerous ... and accurate data input. The pre-defined options ...
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
Medicine Products: